Abstract 73P
Background
Cabozantinib (C), a tyrosine kinase inhibitor against VEGFR2, RET, MET and Axl, has demonstrated clinical activity in RCC and 2L HCC, and has been shown to promote an immune-permissive environment. C is being investigated in clinical trials in combination with immune checkpoint inhibitors (ICI). This preclinical study aimed to determine systemic cytokine profile changes induced by the combination of C + αPD1 and assess cooperativity in anti-tumoral effects.
Methods
Syngeneic colon (CT26, Colon38) and bladder (MBT2) tumour models were established in BALB/C, C57Bl6 or C3H/HEJ mice. C (10 or 30 mg/kg po qd) and αPD1 (10 mg/kg ip 2x weekly) were administered either simultaneously for up to 30 days or with a 14-day delay for αPD1, and serum was collected.
Results
After 30 days' coadministration of C (30 mg/kg) and αPD1, serum cytokines and chemokines (VEGFA, IL3, GM-CSF, MIP1beta, IL17, CCL5, IFNγ, IL10, IL5) were elevated with a median of 72x (range 39–1207x), as compared to 30-days' single administration of αPD1 or C with a median of 3.7x (1.4–135x) and 1.0x (0.5–1.9x), respectively, relative to vehicle-treated animals. Delayed treatment with αPD1 did not result in the same increase in analyte levels as coadministration (median of 1.74x [1–9.9x]). For anti-tumour efficacies, two C doses were explored in CT26 (T/C10/30 67/38% - tumour growth inhibition T/C ratios at 10 or 30 mg/kg), MBT2 (T/C10/30 37/14%) and Colon38 (T/C10/30 21/12%) models. C at 30 mg/kg led to strong anti-tumour efficacy in MBT2 and Colon38, limiting any ICI combinatorial impact to the post-treatment tumour expansion. For CT26 (30 mg/kg) and MBT2 (10 mg/kg), simultaneous dosing of C and αPD1 showed greater anti-tumour effects than single agents despite only limited effects of αPD1 alone. C + αPD1 more than doubled the treatment-specific time that tumours required to reach 1000mm3 compared to C alone.
Conclusions
The results indicate that simultaneous treatment of C + αPD1 leads to strong systemic increases in key cytokines and chemokines and can result in robust anti-tumour efficacy. Our results support the clinical exploration of C + ICI combinations and the potential of this TKI for use in further clinical settings.
Clinical trial identification
Editorial acknowledgement
Isabelle Kaufmann, PhD of Oxford PharmaGenesis, Oxford, UK for provided medical writing support, which was sponsored by Ipsen, Abingdon, UK.
Legal entity responsible for the study
Ipsen.
Funding
Ipsen.
Disclosure
R. Sparks: Full / Part-time employment: Ipsen. S. Rolland: Full / Part-time employment: Ipsen. S. Klinz: Full / Part-time employment: Ipsen. F. Meyer-Losic: Full / Part-time employment: Ipsen. J. Nakhle: Full / Part-time employment: Ipsen. R. Delille: Full / Part-time employment: Ipsen. M. Hillairet de Boisferonc: Research grant / Funding (institution), Contractual obligation: Ipsen.
Resources from the same session
285TiP - Phase II, open-label study of pembrolizumab in children and young adults with newly diagnosed classical Hodgkin lymphoma (cHL) with slow early response (SER) to frontline chemotherapy: KEYNOTE-667
Presenter: Christine Mauz-koerholz
Session: Poster display session
Resources:
Abstract
294P - Validation of the 8th edition of AJCC/UICC staging system for nasopharyngeal carcinoma: Results from a non-endemic cohort with long-term follow-up
Presenter: Li-rong Wu
Session: Poster display session
Resources:
Abstract
295P - Development and validation of M1 substages for previously untreated metastatic nasopharyngeal carcinoma
Presenter: Sik Kwan Chan
Session: Poster display session
Resources:
Abstract
296P - Nasopharyngeal carcinoma: A retrospective review of outcome in a single institution
Presenter: Wan Ping Ch' ng
Session: Poster display session
Resources:
Abstract
297P - Global longitudinal assessment of treatment outcomes in nasopharyngeal carcinoma (GLANCE-NPC) study
Presenter: Myung-Ju Ahn
Session: Poster display session
Resources:
Abstract
298P - Long-term complication and outcomes after induction chemotherapy with TPF followed by chemoradiotherapy for nasopharyngeal cancer
Presenter: Sang-Hee Cho
Session: Poster display session
Resources:
Abstract
299P - Weekly versus triweekly concurrent chemoradiation for nasopharyngeal cancer
Presenter: Sudibio Sudibio
Session: Poster display session
Resources:
Abstract
300P - Endoscopic nasopharyngectomy for localized stage I nasopharyngeal carcinoma
Presenter: Ming-Yuan Chen
Session: Poster display session
Resources:
Abstract
301P - Oncological outcome following 3 Drug NACT for Bucco-Alveolar carcinoma with Supra-notch ITF extension
Presenter: Karan Gupta
Session: Poster display session
Resources:
Abstract
303P - Segmental mandibulectomy without reconstruction
Presenter: Yohei Morishita
Session: Poster display session
Resources:
Abstract